No Data
Pulike Biological Engineering Gets Nod to Market Avian Influenza Vaccine
Pulike Biological Engineering, Inc. (603566.SH) has obtained a new veterinary drug registration certificate.
Pulike Biological Engineering, Inc. (603566.SH) announced that the company and its wholly-owned subsidiary Luoyang Huizhong Biotechnology Co., Ltd. (referred to as "...")
Pulike Biological Engineering, Inc. (603566.SH): In the future, AI technology will be further applied in vaccine development.
On February 27, Glonghui reported that Pulike Biological Engineering, Inc. (603566.SH) stated on the investor interaction platform that AI technology plays a crucial role in key aspects of genetic engineering vaccine development, such as predicting the structure of recombinant proteins, screening antigens, and expression, significantly improving research and development efficiency. We are systematically evaluating cutting-edge AI technologies to achieve in-depth mining of R&D data throughout the entire process while strictly adhering to data security regulations; in the future, we will deepen the application of AI technology in vaccine development, promoting a comprehensive upgrade of the research and development process toward intelligence and precision.
Pulike Biological Engineering, Inc. (603566.SH): Currently, the company's main business will not extend to downstream Farming.
On February 27, Gelonghui reported that Pulike Biological Engineering, Inc. (603566.SH) stated on the investor interaction platform that the company is focused on the animal Health Industry, actively analyzing industry development trends and market demands, striving to solve problems for customers with safe and effective prevention and control products and comprehensive services. Currently, the company's main Business will not extend to the downstream Farming.
Pulike Biological Engineering, Inc. (603566.SH): The African swine fever subunit vaccine is still undergoing emergency evaluation organized by the Ministry of Agriculture and Rural Affairs.
According to a statement on February 27 from Gelonghui, Pulike Biological Engineering, Inc. (603566.SH) mentioned on the investor interaction platform that the African swine fever subunit vaccine developed in collaboration is still undergoing emergency evaluation organized by the Ministry of Agriculture and Rural Affairs.
Individual Investors Among Pulike Biological Engineering, Inc.'s (SHSE:603566) Largest Stockholders and Were Hit After Last Week's 8.5% Price Drop
Benign Growth For Pulike Biological Engineering, Inc. (SHSE:603566) Underpins Stock's 27% Plummet
